Literature DB >> 23419749

Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis.

Herena Eixarch1, Ana Gutiérrez-Franco, Xavier Montalban, Carmen Espejo.   

Abstract

Semaphorins have been classically defined as axonal signalling cues involved in central nervous system (CNS) development, but in adults these molecules are expressed in distinct tissues and exert various functions under several physiological and pathological contexts. Semaphorins capable of modulating the immune system are particularly relevant in autoimmune diseases, especially multiple sclerosis (MS), which is a demyelinating, neurodegenerative disease. In this article, we compile recent insights into the specific roles of semaphorin (sema)3A and sema7A to clarify the details of their possible participation in the inflammatory and neurodegenerative phases of MS.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23419749     DOI: 10.1016/j.molmed.2013.01.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  20 in total

1.  Neuroimmune semaphorin 4A as a drug and drug target for asthma.

Authors:  G Mogie; K Shanks; E H Nkyimbeng-Takwi; E Smith; E Davila; M M Lipsky; L J DeTolla; A D Keegan; S P Chapoval
Journal:  Int Immunopharmacol       Date:  2013-08-28       Impact factor: 4.932

2.  Expression of circulating Semaphorin3A and its association with inflammation and bone destruction in rheumatoid arthritis.

Authors:  Hui Gao; Xiao-Xu Ma; Qian Guo; Lin-Feng Xie; Yu-Chao Zhong; Xue-Wu Zhang
Journal:  Clin Rheumatol       Date:  2018-04-14       Impact factor: 2.980

Review 3.  Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview.

Authors:  Meysam Moghbeli
Journal:  Cell Mol Neurobiol       Date:  2019-09-03       Impact factor: 5.046

4.  Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis.

Authors:  Ana Gutiérrez-Franco; Herena Eixarch; Carme Costa; Vanessa Gil; Mireia Castillo; Laura Calvo-Barreiro; Xavier Montalban; José A Del Río; Carmen Espejo
Journal:  Mol Neurobiol       Date:  2016-10-06       Impact factor: 5.590

Review 5.  Emerging role of semaphorin-3A in autoimmune diseases.

Authors:  Li-Na Liu; Xiao-Mei Li; Dong-Qing Ye; Hai-Feng Pan
Journal:  Inflammopharmacology       Date:  2018-04-25       Impact factor: 4.473

Review 6.  Tripartite synaptomics: Cell-surface proximity labeling in vivo.

Authors:  Tetsuya Takano; Scott H Soderling
Journal:  Neurosci Res       Date:  2021-05-19       Impact factor: 3.304

7.  Semaphorin3A increases M1-like microglia and retinal ganglion cell apoptosis after optic nerve injury.

Authors:  Liu Yun-Jia; Chen Xi; Zhang Jie-Qiong; Zhu Jing-Yi; Lin Sen; Ye Jian
Journal:  Cell Biosci       Date:  2021-05-26       Impact factor: 7.133

8.  Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes.

Authors:  Ranjithkumar Rajendran; Gregor Böttiger; Niklas Dentzien; Vinothkumar Rajendran; Bischand Sharifi; Süleyman Ergün; Christine Stadelmann; Srikanth Karnati; Martin Berghoff
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

9.  Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes.

Authors:  Eiichiro Satake; Pierre-Jean Saulnier; Hiroki Kobayashi; Manoj K Gupta; Helen C Looker; Jonathan M Wilson; Zaipul I Md Dom; Katsuhito Ihara; Kristina O'Neil; Bozena Krolewski; Caterina Pipino; Meda E Pavkov; Viji Nair; Markus Bitzer; Monika A Niewczas; Matthias Kretzler; Michael Mauer; Alessandro Doria; Behzad Najafian; Rohit N Kulkarni; Kevin L Duffin; Marcus G Pezzolesi; C Ronald Kahn; Robert G Nelson; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2021-06-17       Impact factor: 14.978

Review 10.  Neuropilin-1 in transplantation tolerance.

Authors:  Mauricio Campos-Mora; Rodrigo A Morales; Tania Gajardo; Diego Catalán; Karina Pino-Lagos
Journal:  Front Immunol       Date:  2013-11-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.